Cytokinetics, Incorporated (CYTK)
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
Monday, Cytokinetics, Incorporated CYTK announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology Annual Meeting in Bethesda, MD.
Cytokinetics, Incorporated (CYTK) Q2 2024 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Diane Weiser - VP, Corporate Affairs Robert Blum - President, CEO Fady Malik - EVP, R&D Chris Murray - SVP, Regulatory Affairs and Quality Andrew Callos - EVP and Chief Commercial Officer Stuart Kupfer - SVP and Chief Medical Officer Sung Lee - EVP and CFO Conference Call Participants Salim Syed - Mizuho Akash Tewari - Jefferies Roanna Ruiz - Leerink Paul Choi - Goldman Sachs Kripa Devarakonda - Truist Securities Charles Duncan - Cantor Jason Butler - Citizens JMP Sean McCutcheon - Raymond James John Gionco - Needham & Co. Rohan Mathur - Oppenheimer Operator Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Second Quarter 2024 Conference Call. At this time, I would like to inform you that this call is being recorded.
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.
Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1.34 per share a year ago.
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
